The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis
- PMID: 7334410
- PMCID: PMC491235
- DOI: 10.1136/jnnp.44.12.1141
The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis
Abstract
The relationship between plasma levels of pyridostigmine to clinical evaluation of muscle power was examined in nine patients with myasthenia gravis during treatment with pyridostigmine in doses of 60 to 1040 mg daily. Five of the nine subjects demonstrated a trend towards a positive correlation, but in only two of them was this statistically significant at p < 0.05. In addition, the presence or absence of a possible correlation between muscle power and plasma concentration was not related to the duration of the disease, additional prednisolone therapy or thymectomy.
Similar articles
-
Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.Neurology. 1987 May;37(5):800-3. doi: 10.1212/wnl.37.5.800. Neurology. 1987. PMID: 3574680
-
Plasma concentration of pyridostigmine and effects in myastenia gravis.Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):596-601. doi: 10.1002/cpt1977225part1596. Clin Pharmacol Ther. 1977. PMID: 199393
-
Plasma pyridostigmine levels in myasthenia gravis.Neurology. 1981 Feb;31(2):145-50. doi: 10.1212/wnl.31.2.145. Neurology. 1981. PMID: 7193298
-
[Therapy of myasthenia gravis with cholinesterase inhibitors--principles and pharmacologic monitoring].Fortschr Neurol Psychiatr. 1996 Mar;64(3):110-21. doi: 10.1055/s-2007-996377. Fortschr Neurol Psychiatr. 1996. PMID: 8900891 Review. German.
-
Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.Arq Neuropsiquiatr. 2020 Mar;78(3):179-181. doi: 10.1590/0004-282X20190189. Epub 2020 Mar 16. Arq Neuropsiquiatr. 2020. PMID: 32215460 Review.
Cited by
-
Pilot study of pyridostigmine in constipated patients with autonomic neuropathy.Clin Auton Res. 2008 Aug;18(4):194-202. doi: 10.1007/s10286-008-0476-x. Epub 2008 Jul 11. Clin Auton Res. 2008. PMID: 18622640 Free PMC article. Clinical Trial.
-
Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.J Neurol Neurosurg Psychiatry. 1983 Oct;46(10):929-35. doi: 10.1136/jnnp.46.10.929. J Neurol Neurosurg Psychiatry. 1983. PMID: 6644317 Free PMC article.
-
Clinical pharmacokinetics of cholinesterase inhibitors.Clin Pharmacokinet. 1986 May-Jun;11(3):236-49. doi: 10.2165/00003088-198611030-00005. Clin Pharmacokinet. 1986. PMID: 3524957 Review.
-
Influence of food on serum ambenonium concentration in patients with myasthenia gravis.Eur J Clin Pharmacol. 1992;42(4):371-4. doi: 10.1007/BF00280120. Eur J Clin Pharmacol. 1992. PMID: 1516600
-
Pharmacokinetic studies of ambenonium chloride in patients with myasthenia gravis.Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):299-303. doi: 10.1007/BF03189975. Eur J Drug Metab Pharmacokinet. 1991. PMID: 1823874
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical